TTE...JT had a plan to ride the waves on Vascepa and eventually parlay Amarin into a BP...Judge Du put a stop to all that and now Amarin is just floundering with a GIA strategy...We need Denner to install a new sensible plan for Vascepa's future.
This is exactly right. Everyone knows the company should have been sold in 2019. The main reason I would never vote for current leadership is they seem intent on GIA until AMRN is worthless. Imagine waiting for PR's like New Zealand while your cash runs out and generics take the rest of the US market. It's insanity that anyone would support management right now.
Denner has a track record of maximizing shareholder value, and IMO will likely try to find a buyer for whatever he can get. And that is the only play here. Their only asset is worth less every day, and they have no pipeline.
News 
Market Data 
Discover 
AI
